Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ed Schuuring

Showing results (21-30 of 210) with videos related to

Pageof 21
Sort By:
The Oncologist|January 24, 2019
Diagnosis and Treatment Monitoring of a Patient with Gastrointestinal Stromal Tumor by Next-Generation Sequencing and Droplet Digital Polymerase Chain Reaction Assay of a PDGFRA Mutation in Plasma-Derived Cell-Free Tumor DNAPieter A Boonstra, Arja Ter Elst, Marco Tibbesma, et al.
The American Journal of Surgical Pathology|April 24, 2004
Florid granulomatous reaction in Epstein-Barr virus-positive nonendemic Burkitt lymphomas: report of four casesEugenia Haralambieva, Stefano Rosati, Carel van Noesel, et al.
Cellular Oncology (Dordrecht, Netherlands)|July 28, 2012
DNA hypermethylation biomarkers to predict response to cisplatin treatment, radiotherapy or chemoradiation: the present state of artFrank Roossink, Steven de Jong, G Bea A Wisman, et al.
Human Mutation|September 26, 2019
Variation in nomenclature of somatic variants for selection of oncological therapies: Can we reach a consensus soon?Cleo Keppens, Véronique Tack, Kelly Dufraing, et al.
British Journal of Cancer|August 25, 2018
Accreditation, setting and experience as indicators to assure quality in oncology biomarker testing laboratoriesVéronique Tack, Ed Schuuring, Cleo Keppens, et al.
The Journal of Molecular Diagnostics : JMD|March 25, 2020
External Quality Assessment Schemes for Biomarker Testing in Oncology: Comparison of Performance between Formalin-Fixed, Paraffin-Embedded-Tissue and Cell-Free Tumor DNA in PlasmaKaat Van Casteren, Cleo Keppens, Ed Schuuring, et al.
Genes, Chromosomes & Cancer|January 10, 2023
A novel PPP2R2A::PRKD1 fusion in a cribriform adenocarcinoma of salivary glandVincent D de Jager, Sebastiaan A H J de Visscher, Ed Schuuring, et al.
BMC Genomics|February 16, 2005
Comparative genome analysis of cortactin and HS1: the significance of the F-actin binding repeat domainAgnes G S H van Rossum, Ellen Schuuring-Scholtes, Vera van Buuren-van Seggelen, et al.
International Journal of Cancer|November 26, 2002
MYEOV: a candidate gene for DNA amplification events occurring centromeric to CCND1 in breast cancerJohannes W G Janssen, Marguerite Cuny, Béatrice Orsetti, et al.
The Journal of Molecular Diagnostics : JMD|July 29, 2018
Describing the Reportable Range Is Important for Reliable Treatment Decisions: A Multiple Laboratory Study for Molecular Tumor Profiling Using Next-Generation SequencingVéronique Tack, Lien Spans, Ed Schuuring, et al.
Pageof 21

Showing results (21-30 of 210) with videos related to

Sort By:
Pageof 21
The Oncologist|January 24, 2019
Diagnosis and Treatment Monitoring of a Patient with Gastrointestinal Stromal Tumor by Next-Generation Sequencing and Droplet Digital Polymerase Chain Reaction Assay of a PDGFRA Mutation in Plasma-Derived Cell-Free Tumor DNAPieter A Boonstra, Arja Ter Elst, Marco Tibbesma, et al.
The American Journal of Surgical Pathology|April 24, 2004
Florid granulomatous reaction in Epstein-Barr virus-positive nonendemic Burkitt lymphomas: report of four casesEugenia Haralambieva, Stefano Rosati, Carel van Noesel, et al.
Cellular Oncology (Dordrecht, Netherlands)|July 28, 2012
DNA hypermethylation biomarkers to predict response to cisplatin treatment, radiotherapy or chemoradiation: the present state of artFrank Roossink, Steven de Jong, G Bea A Wisman, et al.
Human Mutation|September 26, 2019
Variation in nomenclature of somatic variants for selection of oncological therapies: Can we reach a consensus soon?Cleo Keppens, Véronique Tack, Kelly Dufraing, et al.
British Journal of Cancer|August 25, 2018
Accreditation, setting and experience as indicators to assure quality in oncology biomarker testing laboratoriesVéronique Tack, Ed Schuuring, Cleo Keppens, et al.
The Journal of Molecular Diagnostics : JMD|March 25, 2020
External Quality Assessment Schemes for Biomarker Testing in Oncology: Comparison of Performance between Formalin-Fixed, Paraffin-Embedded-Tissue and Cell-Free Tumor DNA in PlasmaKaat Van Casteren, Cleo Keppens, Ed Schuuring, et al.
Genes, Chromosomes & Cancer|January 10, 2023
A novel PPP2R2A::PRKD1 fusion in a cribriform adenocarcinoma of salivary glandVincent D de Jager, Sebastiaan A H J de Visscher, Ed Schuuring, et al.
BMC Genomics|February 16, 2005
Comparative genome analysis of cortactin and HS1: the significance of the F-actin binding repeat domainAgnes G S H van Rossum, Ellen Schuuring-Scholtes, Vera van Buuren-van Seggelen, et al.
International Journal of Cancer|November 26, 2002
MYEOV: a candidate gene for DNA amplification events occurring centromeric to CCND1 in breast cancerJohannes W G Janssen, Marguerite Cuny, Béatrice Orsetti, et al.
The Journal of Molecular Diagnostics : JMD|July 29, 2018
Describing the Reportable Range Is Important for Reliable Treatment Decisions: A Multiple Laboratory Study for Molecular Tumor Profiling Using Next-Generation SequencingVéronique Tack, Lien Spans, Ed Schuuring, et al.
Pageof 21